Skip to main content
. Author manuscript; available in PMC: 2022 Jan 10.
Published in final edited form as: Eur J Immunol. 2021 Sep 16;51(10):2441–2451. doi: 10.1002/eji.202049150

Figure 3. AP-4-287 repressed SRBC-specific antibodies in the vaccinated mice.

Figure 3.

(A) Representative flow plot showing the mean fluorescent intensity (MFI) of SRBC incubated with plasma from SRBC-vaccinated mice received either vehicle or AP-4-287 treatment and BV421-conjugated anti-mouse IgG1. (B) AP-4-287 reduced the production of SRBC-specific IgG1 in a dose-dependent manner. (C) AP-4-287 did not change the production of pan IgG in vaccinated mice measured with ELISA method. (D) Representative flow plot showing the mean fluorescent intensity (MFI) of SRBC incubated with plasma from SRBC-vaccinated mice received either vehicle or AP-4-287 treatment and PE-conjugated anti-mouse IgM. (E) AP-4-287 reduced the production of SRBC-specific IgM in a dose-dependent manner. (F) AP-4-287 did not change the production of pan IgM in vaccinated mice measured with ELISA method. We used Welch-test to compare the results between two groups. * p<0.05; ** p<0.01. All data are from 2–3 independent experiments with 3–5 mice per experiment.